Omthera Pharmaceuticals

IPO

Public · Princeton, United States · Founded 2009 · $40.4M raised

Employees
1–10
Founded
2009
Business Model
B2B
Total Funding
$40.4M
Last Round
$6.5M Series AMar 2011
Rounds
2
Type
Public

About

Omthera Pharmaceuticals was a Princeton, New Jersey-based specialty pharmaceutical company focused on developing new therapies for dyslipidemia — lipid disorders characterized by elevated triglycerides and increased cardiovascular risk. Founded in 2009, Omthera completed an IPO on Nasdaq (OMTH) in April 2013 and was subsequently acquired by AstraZeneca in August 2013 for approximately $323 million, giving AstraZeneca access to Epanova, a novel omega-3 carboxylic acid treatment for severe hypertriglyceridemia.

Summary

Omthera Pharmaceuticals is a Biotech company based in Princeton, United States, founded in 2009. It has raised $40.4M in total across 2 rounds, most recently a $6.5M Series A round in Mar 2011. Investors include Sofinnova Partners and New Enterprise Associates.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionAcquisition by AstraZenecaMay 2013

Sign up to see all 4 rounds

Series A through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Omthera Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/omthera-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/omthera-pharmaceuticals" alt="Omthera Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>